Baillie Gifford & Co. Sells 189,015 Shares of Elevance Health, Inc. $ELV

Key Points

• Baillie Gifford & Co. trimmed its stake in Elevance Health by 8.7%, selling 189,015 shares and leaving it with 1,977,899 shares (about 0.89% of the company) valued at roughly $693.35 million.
• Analysts have trimmed price targets recently, leaving an average consensus rating of "Hold" with an average price target of $385.38 (12 Buy, 10 Hold, 1 Sell).
• Elevance beat EPS expectations for the quarter ($3.33 vs. $3.10) while revenue was slightly below estimates, raised its quarterly dividend to $1.72 (annualized $6.88, ~2.2% yield), and provided FY2026 EPS guidance of 25.5.

Baillie Gifford & Co. decreased its holdings in shares of Elevance Health, Inc. (NYSE:ELV - Free Report) by 8.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,977,899 shares of the company's stock after selling 189,015 shares during the period. Baillie Gifford & Co. owned 0.89% of Elevance Health worth $693,352,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Artisan Partners Limited Partnership increased its position in shares of Elevance Health by 24.5% during the third quarter. Artisan Partners Limited Partnership now owns 4,576,805 shares of the company's stock valued at $1,478,857,000 after acquiring an additional 901,626 shares during the last quarter. First Eagle Investment Management LLC boosted its stake in Elevance Health by 25.0% during the third quarter. First Eagle Investment Management LLC now owns 3,998,603 shares of the company's stock valued at $1,292,029,000 after buying an additional 798,457 shares during the period. Brave Warrior Advisors LLC boosted its stake in Elevance Health by 65.3% during the third quarter. Brave Warrior Advisors LLC now owns 1,834,002 shares of the company's stock valued at $592,603,000 after buying an additional 724,349 shares during the period. Baupost Group LLC MA boosted its stake in Elevance Health by 114.1% during the third quarter. Baupost Group LLC MA now owns 1,319,000 shares of the company's stock valued at $426,195,000 after buying an additional 703,000 shares during the period. Finally, Hotchkis & Wiley Capital Management LLC lifted its stake in Elevance Health by 44.2% during the third quarter. Hotchkis & Wiley Capital Management LLC now owns 2,045,480 shares of the company's stock worth $660,935,000 after purchasing an additional 627,038 shares during the last quarter. Institutional investors own 89.24% of the company's stock.

Analysts Set New Price Targets

ELV has been the subject of several research analyst reports. Sanford C. Bernstein dropped their price target on Elevance Health from $431.00 to $409.00 and set an "outperform" rating for the company in a research note on Friday, January 30th. Royal Bank Of Canada downgraded Elevance Health from an "outperform" rating to a "sector perform" rating and set a $358.00 price target on the stock. in a report on Tuesday, February 3rd. Truist Financial reduced their target price on Elevance Health from $400.00 to $390.00 and set a "buy" rating on the stock in a report on Monday, February 2nd. Leerink Partners upped their target price on Elevance Health from $350.00 to $357.00 and gave the stock a "market perform" rating in a report on Thursday, January 29th. Finally, Mizuho cut their price target on Elevance Health from $413.00 to $350.00 and set an "outperform" rating on the stock in a research note on Wednesday, March 11th. Twelve research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $385.38.

Elevance Health Trading Up 0.0%

NYSE:ELV opened at $311.54 on Monday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.54 and a quick ratio of 1.54. The firm has a market capitalization of $68.43 billion, a price-to-earnings ratio of 12.40, a price-to-earnings-growth ratio of 1.71 and a beta of 0.49. Elevance Health, Inc. has a one year low of $273.71 and a one year high of $443.29. The business has a fifty day moving average price of $311.25 and a 200-day moving average price of $332.13.

Elevance Health (NYSE:ELV - Get Free Report) last posted its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, topping the consensus estimate of $3.10 by $0.23. The firm had revenue of $49.31 billion during the quarter, compared to analyst estimates of $49.52 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.Elevance Health's revenue was up 9.6% on a year-over-year basis. During the same period in the prior year, the business posted $3.84 EPS. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Sell-side analysts forecast that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, March 25th. Stockholders of record on Tuesday, March 10th were paid a $1.72 dividend. This is a positive change from Elevance Health's previous quarterly dividend of $1.71. The ex-dividend date was Tuesday, March 10th. This represents a $6.88 annualized dividend and a dividend yield of 2.2%. Elevance Health's dividend payout ratio (DPR) is currently 27.39%.

Elevance Health Company Profile

Elevance Health, Inc NYSE: ELV is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company's strategic focus on integrated health care and benefit delivery.

Elevance's core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.